CHMP recommends Duavive for treatment of Oestrogen Deficiency- Pfizer

On 23 October 2014 The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Duavive, 0.45 mg/20 mg modified-release tablets intended for the treatment of Oestrogen Deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The experience treating women older than 65 years is limited. The applicant for this medicinal product is Pfizer Limited and the product is marketed in the US as Duavee.